Related Experiment Videos
Levamisole in prevention of recurrent upper-respiratory-tract infections in children
Insights
Levamisole significantly reduced the frequency, duration, and severity of upper-respiratory-tract infections in children. This immunomodulator demonstrated clear benefits, especially at higher doses, with no reported side effects.
Area of Science:
- Pediatric infectious diseases
- Clinical immunology
- Pharmacology
Background:
- Recurrent upper-respiratory-tract infections (URTIs) pose a significant health burden in children, particularly during colder months.
- Chronic or relapsing URTIs can lead to increased morbidity and healthcare utilization.
Purpose of the Study:
- To evaluate the efficacy of levamisole in managing chronically relapsing mild-to-severe URTIs in pediatric patients.
- To assess the impact of levamisole on the number, duration, and severity of URTI episodes.
Main Methods:
- A six-month, double-blind, placebo-controlled trial involving 70 children with recurrent URTIs.
- Participants received either levamisole (approximately 1.25 mg/kg twice daily for two consecutive days weekly) or a placebo.
- Infections were monitored across three trial periods.
Main Results:
- Levamisole demonstrated statistically significant superiority over placebo in reducing the number, duration, and severity of URTIs.
- A more pronounced therapeutic effect was observed in the subgroup receiving higher doses of levamisole (greater than 2.5 mg/kg/day).
- No adverse drug-related side effects were reported during the trial.
Conclusions:
- Levamisole is an effective therapeutic agent for reducing the burden of recurrent upper-respiratory-tract infections in children.
- The immunomodulatory properties of levamisole appear beneficial in preventing and managing pediatric URTI episodes.
- Levamisole presents a safe and effective treatment option for children suffering from chronic URTIs.
Abstract:
70 children with chronically relapsing mild-to-severe upper-respiratory-tract infections during autumn and winter participated in a six month double-blind placebo-controlled trial: 38 of them received about 1-25 mg/kg of levamisole twice daily for two consecutive days every week, the others were given placebo. During each of the three trial periods, levamisole proved superior to placebo in that it significantly reduced the number, the duration, and the severity of the infections. Moreover, in the group treated with the higher dose (i.e. greater than 2-5 mg/kg/day), the superiority of levamisole to placebo was much more clear-cut. No drug-related side-effects were reported.